Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the type 2 diabetes market in Mexico will grow to $1.22 billion in 2014. Drivers of this growth include increasing prevalent population, expanding medical insurance coverage as well as the launch and use of new drugs in the market.
"Mexico now has the largest type 2 diabetes population in the world behind the United States, China, Japan and India," said Decision Resources Analyst Yannick Maneuf, Ph.D. "As the population ages, the size of Mexico's prevalent type 2 diabetes population will continue to grow. We also expect the diagnosed rate of type 2 diabetes will continue to increase as the Mexican government actively promotes early diagnosis of diabetes."
The new Emerging Markets report entitled Type 2 Diabetes in Mexico also finds that fixed-dose combination therapies constitute the largest drug-class sales with $289 million in sales in 2009 and $332 million expected in 2014. This is due to the uptake of new combinations, such as metformin plus sitagliptin (Merck's Janumet) and metformin plus pioglitazone (Rimsa's Diabamet and Eli Lilly's Competact). Surveyed physicians indicate that metformin and fixed-dosed combinations containing metformin will continue to be the most commonly used agents in Mexico through 2014.
"While metformin continues to be the most widely prescribed oral antidiabetic agent in Mexico, physicians now have more choices for their second- or third-line therapies with newly launched agents coming to market. Our primary research reveals that endocrinologists expect to use these agents more frequently in the next five years despite their high costs," added Dr. Maneuf.
The new report features extensive primary research of Mexican endocrinologists and epidemiology data.
SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients